Document is current
Any future updates will be listed below
-
Authors
Lobo, L Jason
Liu, Yi
Li, Peide
Ramaswamy, Murali
Swaminathan, Aparna C
Veeraraghavan, Srihari
Fan, Yanni
Neely, Megan L
Palmer, Scott M
Olson, Amy L
,
-
Funding
Funding for this research was provided by:
The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) and run in collaboration with the Duke Clinical Research Institute (DCRI) and enrolling centres. (N/A)
- License Information
-
More Information
Article History
Received: 16 October 2023
Accepted: 28 August 2024
First Online: 27 September 2024
Declarations
:
: The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site.
: Not applicable.
: L Jason Lobo, Murali Ramaswamy and Srihari Veeraraghavan are principal investigators in the IPF-PRO/ILD-PRO Registry. Srihari Veeraraghavan also reports research funding paid to Emory Healthcare from Bellerophon Therapeutics, Boehringer Ingelheim, FibroGen, Galactic, Galapagos, Nitto Denko Avecia, Pliant, United Therapeutics; consultancy fees for serving on advisory boards from Boehringer Ingelheim and United Therapeutics; and serves on the Georgia leadership board for the American Lung Association. Yi Liu, Peide Li, Yanni Fan and Amy L Olson are employees of Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Aparna C Swaminathan, Megan L Neely and Scott M Palmer are faculty members of the Duke Clinical Research Institute (DCRI), which receives funding support from BIPI to coordinate the IPF-PRO/ILD-PRO Registry. Aparna C Swaminathan also reports consultancy fees from United Therapeutics. Scott M Palmer also reports research funding paid to DCRI from Bristol Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol Myers Squibb.
: All patients provided informed consent.
